About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
BOARD MEETINGS
Board
Meetings
Transgene Biotek Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
31-Oct-2025
14-Nov-2025
Quarterly Results
30-Jul-2025
07-Aug-2025
Quarterly Results
28-Apr-2025
07-May-2025
Audited Results
17-Jan-2025
24-Jan-2025
Quarterly Results
04-Nov-2024
12-Nov-2024
Quarterly Results & A.G.M.
19-Jul-2024
10-Aug-2024
Quarterly Results
13-May-2024
30-May-2024
Quarterly Results & Audited Results
29-Jan-2024
14-Feb-2024
Quarterly Results
06-Nov-2023
14-Nov-2023
Quarterly Results & Inter alia, to consider and approve:- 2. To consider and approve the appointment of M/s.Vasavi & Co, chartered Accountants as Statutory Auditors of the Company for a period of Five years from the financial year 2023-24 upto-2027-2028, subject to the approval of members in the ensuing annual general meeting. 3. To consider and approve the appointment of M/s.Manisha Dubey, as internal auditor of the Company for financial year 2023-24. 4. To consider and approve the Notice of the 33 rd Annual General meeting for the Financial Year 2022-2023 and other related matters thereto. 5. To consider and approve Directors? Report and the annexure thereon for the Financial Year 2022-2023. 6. To transact such other business as may be required.
17-Jul-2023
05-Aug-2023
Quarterly Results Inter alia, to consider :- 1) To consider and approve the closure of subsidiary company M/s. Peroral Bio Private Limited. 2) To consider and approve an extension for the date of Annual General Meeting (AGM) of the Company for the financial year 2022-23. 3) To consider and approve the appointment of M/s Geeta Serwani & Associates, as Secretarial Auditor of the Company for the financial year 2022-23. 4) To consider and approve the appointment of Ms. Vasavi & Co, as Internal Auditors of the Company for the financial year 2022-23. 5) To transact such other business as may be required.
12-May-2023
30-May-2023
Audited Results
27-Jan-2023
14-Feb-2023
Quarterly Results
04-Nov-2022
12-Nov-2022
Quarterly Results
20-Jul-2022
13-Aug-2022
Quarterly Results & A.G.M.
04-May-2022
30-May-2022
Audited Results
31-Jan-2022
14-Feb-2022
Quarterly Results
03-Nov-2021
12-Nov-2021
Quarterly Results
05-Aug-2021
14-Aug-2021
Quarterly Results
21-Jun-2021
29-Jun-2021
Audited Results Inter alia, 1) To consider and approve the Audited Financial Results of the Company for the Quarter and Financial Year ended on 31 st March 2021. 2) To discuss and approve Service Agreement with NeoDeL Pharma Pvt Ltd. 3) To discuss and approve the change of internal auditors. 4) Any other Business matter, with the permission of the Chair.
18-Jan-2021
23-Jan-2021
Quarterly Results
Page
1
of
6
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.